About LC Bead LUMI

Introducing LC Bead LUMI: The first radiopaque embolic bead

Building on the established clinical performance of LC Bead®, LC Bead LUMI comprises a radiopaque moiety1, allowing for a more precisely controlled procedure and the opportunity to revolutionize the treatment of hypervascular tumors and arteriovenous malformations (AVMs).
 

Why LC Bead LUMI?

LC Bead LUMI is a next-generation development of LC Bead® that provides every time:1

  1. VISION

    Real-time visible confirmation of bead location during embolization.

  2. PRECISION

    The potential to provide increased control by enabling real-time adjustments and enhanced determination of embolization endpoints, therefore optimized patient treatment.

  3. ASSURANCE

    Demonstrate treatment success to your patients, tumor board and inform decisions for future management.


LC Bead LUMI — See More. Treat Smarter


1. VISION

With LC Bead LUMI, you are empowered to see the bead during and after treatment.

During LUMI embolization — see precisely where LC Bead LUMI need to be delivered1.

Begining-of-injection.png Middle-of-injection.png End-of-injection.png
ACC: Beginning of Injection ACC: Middle of Injection    ACC: End of Injection
Fluoroscopy Single shot; images courtesy NIH with permission*.


After LUMI embolization — with lasting radiopacity, LC Bead LUMI continues to be visible in follow-up scans1.

After-NET.png After-HCC.jpg After-ACC.png
NET; 48h FU; MDCT Coronal Plane HCC; 48h FU; MDCT Axial plane ACC; 4 weeks FU; CBCT MIP Axail plane
ACC: adenoid cystic carcinoma; CBCT MIP: Cone-beam computed tomography maximum intensity projection; DSA: digital subtraction angiography; HCC: hepatocellular carcinoma; MDCT: multidetector computed tomography; NET: neuroendocrine tumor. Images courtesy of NIH with permission*.


LC Bead LUMI offers you a new level of control with real-time feedback both during and after embolisation.


2. PRECISION

LC Bead LUMI is designed to offer a more precise and controlled procedure than current techniques.

Guide precise delivery in to tumor1.

Fluoroscopy-DSA-Carcinoid-tumor-Immediatly-post-procedure.png
Shadowing artefact helps highlight treated regions.
Enhanced determination of embolization endpoint1.

HCC-immediatly-post-procedure-(1).png
Vessels filled with beads clearly visable downstream of catheter placement.
Discover regions of undertreatment1.

MDCT-HCC-48th-post-procedure-(1).png
CBCT MIP: Cone-beam computed tomography maximum intensity projection; DSA: digital subtraction angiography; HCC: hepatocellular carcinoma. Images courtesy of NIH with permission*.


LC Bead LUMI enables real-time adjustment during the whole procedure1.


3. ASSURANCE

LC Bead LUMI offers the best opportunity to individualize your patients’ treatment.
LC Bead LUMI offers the precision and control you need to:
 

Modify the procedure in real time1.

Fluoroscopy-DSA-Carcinoid-tumor-Immediatly-post-procedure.png

Shadowing artefact helps highlight treated regions.
Evaluate the completeness of treatment1.

Fusion-image-pre-(contrast-run)-and-immediatly-post-embolisation-CBCT-MIP-with-false-colour-Carcinoid.png Embolized vessels clearly seen in red.
Inform decisions of future patient management1.

48th-post-procedure.jpg

Showing area of under treatment.

CBCT MIP: Cone-beam computed tomography maximum intensity projection; DSA: digital subtraction angiography; HCC: hepatocellular carcinoma; MDCT: multidetector computed tomography; NET: neuroendocrine tumor. Images courtesy of NIH with permission*.


LC Bead LUMI is visible under all standard X-ray imaging modalities

The radiopacity of LC Bead LUMI is equivalent to commonly used contrast agents1no special calibration of equipment is needed.

  • Intra-procedural visualisation: angiography under real time fluoroscopy, x-ray single shot and cone beam computed tomography (CBCT).
  • Post-procedural visualisation: multi-detector computed tomography (MDCT).

 

LC Bead LUMI indication

LC Bead LUMI are intended to be used for the embolization of hypervascular tumors and arteriovenous malformations (AVMs).
 

References
*Images courtesy NIH with permission. Any reference to NIH or the authors should not be viewed as an endorsement of BTG, its products or services.
1. Duran R, et al. Theranostics 2016;6:28–38.